Summit Therapeutics (SMMT) Non Operating Income (2019 - 2026)

Summit Therapeutics has reported Non Operating Income for 8 years, with the latest figure at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 46.98% year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $16.7 million (up 9.29% YoY), and the FY2025 full-year result was $14.8 million, up 10.99% from the prior year.
• Non Operating Income for Q1 2026 stood at $5.8 million, up from $5.8 million in the prior quarter.
• The five-year high for Non Operating Income was $16.1 million in Q4 2023, with the low at -$5.2 million in Q1 2023.
• Historically, Non Operating Income has averaged $2.5 million across 5 years, with a median of $2.4 million in 2025.
• Annual changes were most pronounced in 2022 — Non Operating Income sank 3833.63% — and 2024, when it soared 689.95%.
• Summit Therapeutics' Non Operating Income stood at $5.5 million in 2022, then surged by 194.35% to $16.1 million in 2023, then plunged by 72.55% to $4.4 million in 2024, then jumped by 30.16% to $5.8 million in 2025, then climbed by 0.61% to $5.8 million in 2026.
• The last three Non Operating Income figures came in at $5.8 million (Q1 2026), $5.8 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.